STOCK TITAN

Bionano Adjourns Special Meeting of Stockholders to October 30, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Bionano Genomics (Nasdaq: BNGO) has adjourned its Special Meeting of Stockholders due to lack of quorum. Only 22.5% of total shares were represented, falling short of the required 33.3%. Of the votes submitted, 74.5% were in favor of the proposal. The meeting is rescheduled for October 30, 2024, with voting polls open until October 29. The proposal seeks stockholder approval for issuing common stock upon warrant exercise.

CEO Erik Holmlin emphasized the importance of increased stockholder participation, urging shareholders to vote 'For' the proposal. He warned that failure to approve could adversely affect the company's ability to raise capital and potentially impair its operations and viability.

Bionano Genomics (Nasdaq: BNGO) ha rinviato la sua Riunione Speciale degli Azionisti a causa della mancanza di quorum. Solo il 22,5% delle azioni totali era rappresentato, al di sotto del 33,3% richiesto. Dei voti espressi, il 74,5% era a favore della proposta. La riunione è stata riprogrammata per 30 ottobre 2024, con seggi elettorali aperti fino al 29 ottobre. La proposta richiede l'approvazione degli azionisti per l'emissione di azioni ordinarie a seguito dell'esercizio dei diritti di opzione.

Il CEO Erik Holmlin ha sottolineato l'importanza di una maggiore partecipazione degli azionisti, esortando i soci a votare 'A favore' della proposta. Ha avvertito che il mancato consenso potrebbe pregiudicare la capacità della società di raccogliere capitali e potenzialmente comprometterne le operazioni e la sostenibilità.

Bionano Genomics (Nasdaq: BNGO) ha pospuesto su Junta Especial de Accionistas debido a la falta de quórum. Solo el 22.5% de las acciones totales estuvo representado, fallando en alcanzar el 33.3% requerido. De los votos emitidos, el 74.5% estuvo a favor de la propuesta. La reunión se ha reprogramado para 30 de octubre de 2024, con las urnas abiertas hasta el 29 de octubre. La propuesta busca la aprobación de los accionistas para la emisión de acciones comunes al ejercer las opciones.

El CEO Erik Holmlin enfatizó la importancia de una mayor participación de los accionistas, instando a los accionistas a votar 'A favor' de la propuesta. Advirtió que la falta de aprobación podría afectar negativamente la capacidad de la empresa para recaudar capital y potencialmente perjudicar sus operaciones y viabilidad.

Bionano Genomics (Nasdaq: BNGO)는 의사 정족수 부족으로 주주 특별 회의를 연기했습니다. 전체 주식의 22.5%만이 참석하여 요구되는 33.3%에 미치지 못했습니다. 제출된 투표 중 74.5%가 제안에 찬성했습니다. 회의는 2024년 10월 30일로 재조정되었으며, 투표는 10월 29일까지 가능합니다. 제안은 옵션 행사 시 보통주 발행에 대한 주주 승인을 요청하고 있습니다.

CEO Erik Holmlin은 주주 참여의 중요성을 강조하며 주주들에게 제안에 대해 '찬성' 투표를 할 것을 촉구했습니다. 그는 승인을 받지 못할 경우 회사가 자본을 모으는 능력에 부정적인 영향을 미칠 수 있다고 경고하며, 이는 회사의 운영 및 생존 가능성에 잠재적으로 악영향을 미칠 수 있습니다.

Bionano Genomics (Nasdaq: BNGO) a reporté sa Réunion Spéciale des Actionnaires en raison d'un manque de quorum. Seules 22,5% des actions totales étaient représentées, en dessous du 33,3% requis. Parmi les votes exprimés, 74,5% étaient en faveur de la proposition. La réunion est reprogrammée pour le 30 octobre 2024, avec des urnes ouvertes jusqu'au 29 octobre. La proposition demande l'approbation des actionnaires pour l'émission d'actions ordinaires lors de l'exercice des bons.

Le PDG Erik Holmlin a souligné l'importance d'une plus grande participation des actionnaires, exhortant ceux-ci à voter 'Pour' la proposition. Il a averti que le refus pourrait avoir un impact négatif sur la capacité de l'entreprise à lever des fonds et pourrait potentiellement nuire à son fonctionnement et à sa viabilité.

Bionano Genomics (Nasdaq: BNGO) hat seine ausserordentliche Hauptversammlung der Aktionäre aufgrund von Quorum-Mangel vertagt. Nur 22,5% der Gesamtaktien waren vertreten, was unter dem erforderlichen Wert von 33,3% liegt. Von den abgegebenen Stimmen waren 74,5% für den Vorschlag. Die Versammlung ist neu terminiert auf 30. Oktober 2024, die Abstimmung ist bis zum 29. Oktober geöffnet. Der Vorschlag sieht die Genehmigung der Aktionäre zur Ausgabe von Stammaktien bei Ausübung von Optionen vor.

CEO Erik Holmlin betonte die Bedeutung einer höheren Teilnahme der Aktionäre und forderte die Aktionäre auf, 'Für' den Vorschlag zu stimmen. Er warnte, dass eine Ablehnung die Fähigkeit des Unternehmens zur Kapitalbeschaffung negativ beeinflussen und potenziell dessen Betrieb und Lebensfähigkeit beeinträchtigen könnte.

Positive
  • 74.5% of submitted votes were in favor of the proposal
Negative
  • Special Meeting adjourned due to lack of quorum (22.5% vs required 33.3%)
  • Failure to approve the proposal may negatively impact the company's ability to raise capital
  • Low stockholder participation in voting process

Special Meeting of Stockholders Adjourned Due to Lack of Quorum

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it has adjourned its Special Meeting of Stockholders held on October 2, 2024 (the “Special Meeting”) because a quorum was not present at the time of meeting. Based on preliminary reports as of October 2, 2024, only 22.5% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting. Based on the preliminary reports from the votes submitted as of October 2, 2024, approximately 74.5% of votes represented in person or by proxy at the Special Meeting were voted “For” the proposal.

The Special Meeting will reconvene at 10 a.m. Pacific Time on October 30, 2024. Voting polls will remain open until 11:59 p.m. Eastern Time on October 29, 2024. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

Stockholders of record may vote their shares by calling Toll-Free at 1-800-690-6903. Further information on the company’s proxy proposal soliciting stockholder approval for the issuance of common stock upon the exercise of warrants may be found in the company’s definitive proxy statement filed with the Securities and Exchange Commission on August 21, 2024 and available at: 
https://www.sec.gov/Archives/edgar/data/1411690/000114036124038087/ny20032632x2_def14a.htm.

Before making any voting decisions stockholders are urged to read the company’s definitive proxy statement because it contains important information about the proposal and the Special Meeting. No changes have been made to the proposal to be voted on by stockholders at the Special Meeting.

Erik Holmlin, PhD, CEO of Bionano commented, “We are extremely grateful to our stockholders who made their voices heard through the voting process. However, only approximately 22.5% of our shares were voted at the meeting, and we were short by approximately 9.2 million votes. We have adjourned the meeting to allow time for increased stockholder participation.

“For this reason, we ask that you vote ‘For’ the proposal. If you have not yet voted your shares, we encourage you to vote ‘For’ the proposal. If you have voted against this proposal, you can change your vote, and we ask that you consider doing so. The failure of our stockholders to approve the proposal may materially adversely affect the Company’s future ability to raise equity or debt capital from third parties on attractive terms, if at all, and also risks significantly impairing the operations, assets and ongoing viability of the Company. As always, we are grateful to all the stockholders for their participation.”

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit www.bionano.com and www.bionanolaboratories.com . 

Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “estimate,” “expect,” “may,” “plan,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the date for the reconvened meeting, and the potential negative impacts to the company if stockholders do not approve the issuance of common stock upon exercise of the warrants. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of approving the issuance of common stock upon exercise of the warrants; the impact of adverse geopolitical and macroeconomic events, such as recent and potential future bank failures and the ongoing conflicts between Ukraine and Russia and Israel and Hamas, on our business and the global economy; general market conditions, including inflation and supply chain disruptions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS

Company Contact:

Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:

David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com


FAQ

Why did Bionano Genomics (BNGO) adjourn its Special Meeting of Stockholders?

Bionano Genomics adjourned its Special Meeting due to lack of quorum. Only 22.5% of total shares were represented, falling short of the required 33.3%.

When is the rescheduled Special Meeting for Bionano Genomics (BNGO)?

The Special Meeting has been rescheduled for October 30, 2024, at 10 a.m. Pacific Time. Voting polls will remain open until 11:59 p.m. Eastern Time on October 29, 2024.

What percentage of votes were in favor of Bionano Genomics' (BNGO) proposal?

Approximately 74.5% of votes represented at the Special Meeting were voted in favor of the proposal.

What is the potential impact if Bionano Genomics' (BNGO) proposal is not approved?

Failure to approve the proposal may adversely affect the company's ability to raise equity or debt capital, and could potentially impair its operations, assets, and ongoing viability.

Bionano Genomics, Inc.

NASDAQ:BNGO

BNGO Rankings

BNGO Latest News

BNGO Stock Data

26.52M
95.88M
0.15%
12.63%
8.92%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO